Drugs / BDC-3042
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06052852 | Oct 2023 → Aug 2025 | clear cell renal carcinoma, colorectal cancer, head and neck cancer, melanoma +3 | Bolt Biotherapeutics, Inc. | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BDC-3042 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06052852 ↗ |
| Action | Activate | “Dectin-2 agonist antibody” NCT06052852 ↗ |
| Modality | Monoclonal antibody | “Dectin-2 agonist antibody” NCT06052852 ↗ |